• Bufalin Targets STK33 for Triple-Negative Breast Cancer Ther

  2026-05-11

  This article reviews a recent study identifying serine/threonine kinase 33 (STK33) as a direct molecular target of Bufalin in triple-negative breast cancer (TNBC). The findings clarify Bufalin’s mechanism of action in TNBC, demonstrating its ability to degrade STK33 and inhibit tumor growth, and provide new directions for targeted cancer research.

• Afatinib (BIBW 2992): Powering Tumor Assembloid Cancer Resea

  2026-05-11

  Afatinib, an irreversible ErbB family tyrosine kinase inhibitor, elevates the precision and translational relevance of cancer biology research in next-generation assembloid models. Discover how its robust inhibition profile and compatibility with patient-derived systems enable researchers to decode resistance mechanisms and optimize targeted therapies.

• PTH (1-34) Peptide: Driving Translational Advances in Bone a

  2026-05-10

  This thought-leadership article presents a mechanistic and strategic analysis of Parathyroid hormone (1-34) (human), highlighting its role in bone metabolism, serum calcium regulation, and CKD-associated valvular calcification. Integrating new insights from endothelial Foxp1/Notch signaling, it provides actionable guidance for translational researchers seeking robust, reproducible models and optimized protocols. Distinct from standard product pages, this piece forges novel conceptual bridges and references benchmark content to set a new standard in PTH (1-34) application.

• CLCC1 Identified as a Key Host Factor in Herpesvirus Nuclear

  2026-05-09

  A recent study reveals that the chloride channel CLCC1 is essential for the membrane fusion step of herpesvirus nuclear egress, a critical stage for viral maturation and infectivity. This discovery advances the mechanistic understanding of host-virus interactions and offers new perspectives for antiviral research.

• Radicicol: Advanced Strategies for Inflammation and Cell Fat

  2026-05-08

  Explore how Radicicol, a leading Hsp90 inhibitor, enables precision modulation of inflammation and cell fate in cutting-edge research. This article uniquely connects Radicicol’s multifaceted mechanism to mitochondrial and senescence pathways, revealing advanced applications for translational studies.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-08

  Schwartz’s dissertation provides a rigorous comparative framework distinguishing proliferative arrest from cell death in anti-cancer drug response assays. This nuanced approach advances preclinical evaluation by clarifying how agents like Everolimus (RAD001) differentially impact cancer cell fate and supports improved experimental design for translational studies.

• CPI-613: Mechanism and Benchmarks for Tumor Cell Metabolism

  2026-05-07

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) is a first-in-class mitochondrial metabolism inhibitor for cancer research. It selectively targets PDH and KGDH, impairs tumor bioenergetics, and demonstrates potent apoptosis induction in preclinical models. This dossier provides atomic, evidence-based insights for optimizing apoptosis assays and tumor metabolism workflows.

• Cardiac Biomarkers in Epileptic Baboons: Insights into SUDEP

  2026-05-07

  This study identifies QT-interval prolongation and reduced heart rate variability as cardiac biomarkers linked to epilepsy in a pedigreed baboon model. The findings provide a translational foundation for assessing SUDEP risk and foster cross-species understanding of epilepsy-associated cardiac alterations.

• CP-673451: Precision PDGFRα/β Inhibition for ATRX-Deficient

  2026-05-06

  Explore how CP-673451, a selective PDGFRα/β inhibitor, unlocks new frontiers in cancer research—especially for ATRX-deficient glioma studies. This article offers advanced protocol insights and practical guidance beyond standard applications.

• GSTA1 Drives Glutathione Loss in α-Amanitin Liver Toxicity

  2026-05-06

  This study reveals that GSTA1, commonly viewed as a hepatic detoxifier, paradoxically worsens α-amanitin-induced liver injury by accelerating glutathione depletion and oxidative stress. These findings reposition GSTA1 as a direct pathogenic factor and highlight new therapeutic and biomarker opportunities in acute hepatotoxicity.

• Novel PDK4 Inhibitors for Oral Therapy of Metabolic Diseases

  2026-05-05

  This article reviews the identification and characterization of potent, orally bioavailable pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, with a focus on compound 8c, as reported by Lee et al. (2019). The study's findings provide a strong foundation for targeting PDK4 in metabolic, allergic, and oncological disease models, and offer a scaffold for future drug development.

• Baicalin in Adult Visual Plasticity: Novel Mechanisms & Assa

  2026-05-05

  Explore how Baicalin modulates KEAP1-NRF2/HO-1 and TGF-β1/p-Smad3 pathways to restore visual plasticity in adult amblyopia, with advanced protocol guidance and practical implications for translational neuroscience. This article offers unique, evidence-based insights for researchers optimizing Baicalin applications.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Tumo

  2026-05-04

  The reference study establishes anlotinib hydrochloride as a highly potent and selective multi-target tyrosine kinase inhibitor, with particular efficacy against VEGFR2 in angiogenesis models. Its robust anti-angiogenic activity, favorable pharmacology, and in vivo efficacy mark it as a valuable tool for cancer research and preclinical drug development.

• Eicosapentaenoic Acid (EPA): Mechanisms, Evidence, and Proto

  2026-05-04

  Eicosapentaenoic Acid (EPA) is a well-characterized EPA omega-3 fatty acid with proven lipid-lowering and anti-inflammatory effects in cardiovascular disease research. EPA modulates membrane composition, inhibits endothelial cell migration, and enhances prostaglandin I2 production, supporting its use as a research-grade anti-inflammatory compound. This article details EPA’s mechanisms, benchmarks, and workflow integration with robust citations.

• Anlotinib Hydrochloride: Advancing Translational Angiogenesi

  2026-05-03

  This thought-leadership article examines Anlotinib hydrochloride as a next-generation multi-target tyrosine kinase inhibitor, blending mechanistic insight, experimental validation, and strategic guidance for translational researchers. By integrating peer-reviewed evidence, including its application in rare sarcomas, and benchmarking against established agents, the article demonstrates how APExBIO's rigorously characterized compound empowers robust, reproducible anti-angiogenic workflows beyond standard summaries.

16565 records 1/1105 page Next 12345 下5页 Last page